Hawaii 2022 Regular Session

Hawaii Senate Bill SB1192

Introduced
1/27/21  
Refer
1/29/21  
Report Pass
2/17/21  
Refer
2/17/21  
Report Pass
3/4/21  
Engrossed
3/5/21  

Caption

Relating To The Electronic Prescription Accountability System.

Impact

If passed, SB1192 will directly influence how controlled substances are managed and tracked across Hawaii. The amendments mandate frequent reporting of dispensations, including instances where no controlled substances were filled, effectively fostering a more accountable prescription environment. Additionally, it extends the responsibility to maintain detailed records that are subject to scrutiny by state regulators, thus increasing oversight of pharmaceutical practices. The overall goal is to reduce the potential for opioid overdoses and related harms by improving the transparency of prescription activity.

Summary

Senate Bill 1192 aims to enhance the enforcement of the Electronic Prescription Accountability System in Hawaii by amending the provisions within the Hawaii Revised Statutes. The bill focuses on requiring all practitioners and pharmacies to report the dispensing of controlled substances and pharmacist-prescribed opioid antagonists to a central repository. This change is designed to mitigate the misuse and abuse of controlled substances within the state, particularly in the context of the ongoing opioid crisis. By ensuring comprehensive reporting practices, the bill seeks to improve the state's monitoring capabilities and ultimately enhance public health outcomes.

Sentiment

The sentiment surrounding SB1192 appears to be supportive among public health and regulatory advocates who prioritize tackling substance abuse issues. Advocates assert that the proposed amendments will provide crucial tools for combatting opioid misuse and enhancing the efficacy of monitoring systems. However, concerns have also been raised regarding the administrative burden placed on practitioners and pharmacies in compliance with the new reporting requirements. Opponents fear that the increased regulatory framework might complicate the prescription process and inadvertently impact patient care, reflecting the tension between regulatory oversight and healthcare accessibility.

Contention

Notable points of contention regarding SB1192 include the balance between necessary oversight and the potential operational challenges for healthcare providers. While many agree on the need for an electronic accountability system to combat opioid misuse, there are apprehensions about the implications of reporting frequency and record-keeping requirements. Critics argue that added administrative tasks might detract from the time practitioners can spend with patients, particularly in critical areas such as pain management. The bill's passage may also hinge on striking a balance between improving public health protection and ensuring that healthcare providers can continue to deliver effective care without excessive regulatory scrutiny.

Companion Bills

HI HB1038

Same As Relating To The Electronic Prescription Accountability System.

Similar Bills

CT HB07395

An Act Concerning Opioid Abuse And Treatment.

AZ SB1211

Pharmacists; prescribing; naloxone; reporting

HI SB2033

Relating To The Electronic Prescription Accountability System.

HI HB1038

Relating To The Electronic Prescription Accountability System.

CT HB05053

An Act Concerning Opioids And Access To Overdose Reversal Drugs.

CT HB07052

An Act Preventing Prescription Opioid Diversion And Abuse.

CT HB06856

An Act Concerning Substance Abuse And Opioid Overdose Prevention.

CT SB00511

An Act Concerning Opioids.